Results for this period
Interim period (second quarter)1 April 2026 to 30 September 2026ConsolidatedJapanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ thousand).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
Revenue in the Medical business declined as advertising investment was restrained in response to changes in the market environment. Improved earnings in Media Services, the recovery in advertising rates and page views, the SaaS and DX businesses turning profitable, growth in paying subscribers to 10-gigabit fiber-optic and MVNO services, and customer acquisition for FanGrowth and Sharely contributed to performance.
None
| Item | Details |
|---|---|
| Fiscal Period Classification | Interim period (second quarter) |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 April 2026 to 30 September 2026 |
| Net Sales | ¥5,113 million (YoY -0.2%) |
| Operating profit | ¥280 million (YoY +186.3%) |
| Ordinary income | ¥295 million (YoY +211.6%) |
| Profit attributable to owners of the parent | ¥311 million |
| Net income per share | ¥64.79 |
| Equity ratio | End of the current fiscal period 34.8 / End of previous period 32.3 |
| Total assets | ¥10,552 million |
| Net assets | ¥3,829 million |
| Cash flows from operating activities | ¥449,419 thousand |
| Cash flows from investing activities | ¥-546,164 thousand |
| Cash flows from financing activities | ¥-596,681 thousand |
| Cash and cash equivalents at end of period | ¥1,597,758 thousand |
| Full-year earnings forecast | Net Sales ¥12,000 million (YoY +11.1%) / Operating profit ¥610 million (YoY +34.3%) / Ordinary income ¥560 million (YoY +32.9%) / Net income ¥350 million (YoY +38.2%) |
| Annual Dividend Forecast | 31.5 yen → 32.7 yen（+3.8%） |
| Segment revenue | Medical Business ¥1,023,433 thousand (YoY -14.0%), Platform Business ¥1,746,804 thousand (YoY +4.1%), Broadband business ¥1,865,048 thousand (YoY +3.3%), SaaS and DX Business ¥480,586 thousand (YoY +6.1%) |
| Segment profit | Medical Business ¥-134,598 thousand, Platform Business ¥370,637 thousand (YoY +91.7%), Broadband business ¥255,526 thousand (YoY -5.1%), SaaS and DX Business ¥41,280 thousand |
| Depreciation and amortization | ¥145,383 thousand |
| Impairment loss | None (impairment losses on fixed assets and other items by reportable segment) |
| Breakdown of extraordinary income (loss) | No extraordinary gains or extraordinary losses were recorded for the interim period. |
| Disclosure regarding the going concern assumption | None |
| Change in accounting policy | Changes due to revisions to standards None / Other changes None / Change in accounting estimate None / Restatement None |
| Changes in the scope of consolidation | New Number of companies 1 / Company name Open Cure㈱ / Excluded Number of companies 1 / Company name iXIT㈱ |
| Material subsequent events | None |
| Availability of Supplementary Financial Results Materials | Available |
| Availability of Financial Results Briefing | Whether applicable Available / Subject person Institutional investors and analysts |
| Issued Shares at Period-End | 4,878,690 |
| Treasury Shares at Period-End | 74,000 |
| Factors Behind Changes in Business Performance | Revenue in the Medical business declined as advertising investment was restrained in response to changes in the market environment. Improved earnings in Media Services, the recovery in advertising rates and page views, the SaaS and DX businesses turning profitable, growth in paying subscribers to 10-gigabit fiber-optic and MVNO services, and customer acquisition for FanGrowth and Sharely contributed to performance. |
Items this document does not state (6)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Revenue in the Medical business declined as the company restrained advertising investment in response to changes in the market environment, prioritising improvements in unit economics. Meanwhile, improved earnings in Media Services, the SaaS and DX businesses turning profitable, the recovery in advertising rates and page views, growth in paying subscribers to 10-gigabit fiber-optic and MVNO services, and customer acquisition for SaaS services contributed to improved earnings.